Literature DB >> 563233

Biologic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-D-arabinofuranosyladenine.

R W Brockman, F M Schabel, J A Montgomery.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 563233     DOI： 10.1016/0006-2952(77)90275-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  21 in total

1.  Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine.

Authors:  A A Adjei; L Dagnino; M M Wong; A R Paterson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 inhibitors.

Authors:  Luminita Crisan; Sorin Avram; Liliana Pacureanu
Journal:  Mol Divers       Date:  2017-01-21       Impact factor: 2.943

3.  Pharmacokinetic study of fludarabine phosphate (NSC 312887).

Authors:  M R Hersh; J G Kuhn; J L Phillips; G Clark; T M Ludden; D D Von Hoff
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 4.  Cellular and clinical pharmacology of fludarabine.

Authors:  Varsha Gandhi; William Plunkett
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 6.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

7.  Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas. An Illinois Cancer Center study.

Authors:  L J Kilton; A B Benson; A Greenberg; P Johnson; C Shapiro; R Blough; S French; L Weidner
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

8.  6-N-substituted derivatives of adenine arabinoside as selective inhibitors of varicella-zoster virus.

Authors:  G W Koszalka; D R Averett; J A Fyfe; G B Roberts; T Spector; K Biron; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  Phase I clinical trial of fludarabine phosphate (F-ara-AMP).

Authors:  E S Casper; A Mittelman; D Kelson; C W Young
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Fludarabine in the treatment of chronic lymphocytic leukemia: a review.

Authors:  Francesca Ricci; Alessandra Tedeschi; Enrica Morra; Marco Montillo
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.